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Abstract
Paediatric age groups display important differences in host biology, predisposing conditions, epidemiology and presentation of fungal infec-
tions relative to the adult population. During the past decade, several new antifungal agents have been developed. Although not all of
these agents are yet approved for children, the paediatric development of antifungal agents has moved forwards in an exemplary manner.
Invasive fungal infections will remain important causes of morbidity and mortality in immunocompromised paediatric patients. Whereas
the availability of new therapeutic options is an important advance, antifungal therapy has become increasingly complex, and a thorough
understanding of the available antifungal armamentarium is essential for the successful management of the individual patient. This article
provides an update on the pharmacokinetics, safety and dosing of antifungal agents in paediatric patients, and their clinical indications.
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Introduction
Invasive fungal infections have evolved into important
causes of morbidity and mortality in children with severe
underlying illnesses. Irrespective of age and underlying con-
dition, these infections remain difﬁcult to diagnose, and
responses to treatment depend on early diagnosis and
prompt initiation of appropriate treatment. Apart from a
better understanding of both the pharmacology and clinical
indications of existing antifungal agents, recent years have
witnessed the development of new broad-spectrum triaz-
oles and the advent of the new class of echinocandins
(Fig. 1). Children, in particular neonates and young infants,
represent a unique patient population, in particular with
regard to the disposition of antifungal agents and safety
issues; however, antifungal pharmacodynamics may also be
different, as emerging data on treatment approaches for
central nervous system infections in premature neonates
suggest. This article provides a brief update on the
pharmacokinetics, safety and dosing of antifungal agents in
paediatric patients, their clinical indications in the manage-
ment of opportunistic fungal infections, and the current
status of regulatory approval, with a focus on recent
developments.
Established Antifungal Agents
Amphotericin B deoxycholate
The pharmacokinetics of amphotericin B deoxycholate in
paediatric patients are characterized by high inter-individual
variability, but are not different from those observed in
adults [1]. Infusion-related reactions, although rarely
observed in neonates, and, even more, nephrotoxicity often
limit treatment with amphotericin B deoxycholate [2–8]. In
countries where alternative options are available, few indica-
tions are therefore left for antifungal treatment with ampho-
tericin B deoxycholate. These include neonatal invasive
candidiasis and induction therapy for cryptococcal meningitis.
The recommended daily dosage in these settings ranges from
0.7 to 1.0 mg/kg daily administered over 2–4 h as tolerated;
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treatment should be started at the full target dosage with
careful clinical monitoring.
Lipid formulations of amphotericin B
The lipid formulations of amphotericin B (amphotericin B
colloidal dispersion (Amphocil or Amphote), amphotericin B
lipid complex (Abelcet) and liposomal amphotericin B (AmBi-
some) allow for the safe delivery of higher dosages of the
parent compound [9]. Each of the lipid formulations pos-
sesses distinct physicochemical and pharmacokinetic proper-
ties. Whether and how these distinct features translate into
different pharmacodynamics in vivo is not well characterized.
The available pharmacokinetic and safety data for the lipid
formulations of amphotericin B in paediatric age groups indi-
cate no fundamental differences relative to the adult popula-
tion [4,10–21] (48th ICAAC, Abstract A-005, Walsh T,
2008) (Table 1). Taken together, the lipid formulations have
less renal toxicity as deﬁned by development of azotaemia
than conventional amphotericin B; distal tubular toxicity also
may be somewhat reduced. Infusion-related side effects of
fever, chills and rigor are substantially less frequent with lipo-
somal amphotericin B only, whereas the infusion-related
reactions of amphotericin B colloidal dispersion and ampho-
tericin B lipid complex appear to be similar to those of
amphotericin B deoxycholate. Mild increases in serum biliru-
bin and alkaline phosphatase can be observed with all three
formulations, and mild increases in serum transaminases with
liposomal amphotericin B [9,22].
Currently, amphotericin B colloidal dispersion is licensed
for treatment of patients with invasive aspergillosis refractory
to, or who are intolerant to, amphotericin B deoxycholate,
and amphotericin B lipid complex for treatment of patients
with invasive Candida and Aspergillus infections refractory to,
or who are intolerant to, amphotericin B deoxycholate;
amphotericin B lipid complex may also be indicated for ﬁrst-
line treatment of zygomycosis [22]. Liposomal amphoteri-
cin B has approved ﬁrst-line indications for empirical therapy
of persistently neutropenic patients and for treatment of
invasive mycoses, including invasive aspergillosis [23] and
invasive candidiasis [24]. The recommended therapeutic dos-
ages are 3–4 mg/kg per day for amphotericin B colloidal dis-
persion, 5 mg/kg daily for amphotericin B lipid complex, and
3 (to 5) mg/kg daily for liposomal amphotericin B [22]. The
therapeutic dosage for treatment of zygomycosis should not
be <5 mg/kg daily. As for to amphotericin B deoxycholate,
treatment should be started with the full target dosage at
the infusion rate recommended by the manufacturer.
5-Fluorocytosine
5-Fluorocytosine is a fungus-speciﬁc synthetic base analogue
that has useful antifungal activity against Candida and Crypto-
coccus species [22,25]. An established indication for 5-ﬂuoro-
cytosine is its use in combination with amphotericin B
deoxycholate for induction therapy for cryptococcal meningi-
tis [26,27]. The combination with amphotericin B may also
be an option for the treatment of Candida infections involv-
ing deep tissues [25] including Candida meningitis [28–30];
however, the optimal management of Candida meningitis and
meningoencephalitis is unknown [31].
Although separate pharmacokinetic data for infants and
children are lacking, extreme inter-individual variability in
TABLE 1. Pharmacokinetic param-
eters of amphotericin B lipid for-
mulations
ABCD ABLC LAMB
P (5) A (7) P (3) A (8) P (5) A (9)
Dose (mg/kg) 7–7.5 7–7.5 2.5 2.5 5 5.0
Cmax (lg/mL) NA NA 1.69 2.41 57 83
AUC0–24 (lg/mL/h) 7.10 9.60 11.9 6.77 482 555
VD (L/kg) 4.57 4.21 NA 105 0.53 0.10
CLt (L/kg/h) 0.144 0.111 0.218 0.300 0.017 0.011
AUC0–24, area under the concentration-time curve from 0–24 hours; Cmax, peak plasma concentrations; CLt, total
clearance; NA, not available; VD, volume of distribution.
Depicted are mean values after multiple dosing in padiatric (P) relative to adult (A) patients. Compiled from refer-
ences [4,10–21] and 48th ICAAC, Abstract A-005.
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FIG. 1.Overview of current antifungal agents available for the
management of invasive fungal infections and their cellular targets.
Agents approved for paediatric patients are in bold type. ABCD,
amphotericin B colloidal dispersion; ABLC, amphotericin B lipid
complex; DAMB, amphotericin B deoxycholate; LAMB, liposomal
amphotericin B.
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clearance and distribution volume has been reported in
neonates [32]. Although recent analyses of therapeutic drug
monitoring (TDM) data in children and pharmacokinetic
bridging models suggest that lower dosages may be more
appropriate [33,34], the approved starting dosage of 100 mg/
kg daily divided into three or four doses is currently recom-
mended for both adults and children. TDM is advised; peak
plasma levels between 40 and 60 lg/mL correlate with
antifungal activity, but are seldom associated with marrow
toxicity [35].
Antifungal triazoles
The antifungal triazoles have become an important compo-
nent of the antifungal armamentarium. Whereas ﬂuconazole
and itraconazole have been available for more than a decade,
voriconazole and posaconazole have entered clinical practice
only recently [25] (Fig. 2).
Fluconazole. With the exception of premature neonates,
where clearance may be decreased during the ﬁrst days of
life, paediatric patients tend to have greater normalized
plasma clearance and a shorter half-life than adults [36–39]
(Table 2). Therefore, relative to weight, higher dosages are
required in children to achieve comparable exposures.
In paediatric patients, at dosages of up to 12 mg/kg daily,
ﬂuconazole is generally well tolerated [40]. The most
common reported side effects include gastrointestinal
disturbances (8%), increases in hepatic transaminases (5%)
and skin reactions (1%); toxicity-related discontinuations
occur in approximately 3% of patients [40]. Severe side
effects, including relevant hepatotoxicity and exfoliative skin
reactions, have been reported anecdotally [25].
Fluconazole may be used for invasive Candida infections
caused by susceptible organisms in paediatric patients of all
ages who are in a stable condition and who have not
received prior azole therapy [22, 41–47]. The recommended
dosage range beyond the neonatal period is 6–12 mg/kg
daily; in view of the faster clearance rate and the absence of
population pharmacokinetics, however, 12 mg/kg daily may
be the most appropriate dosage. For infants, population-
based pharmacokinetics and Monte Carlo simulation showed
that for the treatment of invasive candidiasis, a dose of at
least 12 mg/kg daily in the ﬁrst 90 days after birth is needed
C
C
Itraconazole
Posaconazole
Fluconazole
Voriconazole
N
N
N
F
F
O
O N N N
N
N
O
OH
CH3
N
N
N
F
F
OH
CH3
N
N
F
N
N
N
Cl
Cl
O
O
O N N N N
N
O
N
N
N
F
F
N
N
N
OH
FIG. 2. Chemical structures of the antifungal triazoles. Whereas voriconazole is structurally related to ﬂuconazole, posaconazole is related to
itraconazole.
TABLE 2. Pharmacokinetic parameters of ﬂuconazole in
pediatric patients
Age group VDss (L/kg) Cl (L/h/kg) t1/2 beta (h)
Preterm <1500 g
Day 1 1.18 0.010 88
Day 6 1.84 0.019 67
Day 12 2.25 0.031 55
Term neonates 1.43 0.036 28
Infants >1–6 months 1.02 0.037 19
Children 5–15 years 0.84 0.031 18
Adult volunteers 0.65 0.015 30
Data represent mean values and are compiled from [36–38].
Cl, total plasma clearance; t1/2 beta, elimination half-life; VDss, apparent volume
of distribution at steady state.
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to achieve an area under the concentration curve/MIC
index >50 for Candida species with MIC <8 mg/L in ‡90% of
<30-week-gestation infants and 80% of 30–40-week-gestation
infants, respectively; according to the model, infants with
serum creatinine ‡1.3 mg/dL have a slower clearance rate,
and dose adjustment is indicated if creatinine does not
improve within 96 h [39,48].
Further potential therapeutic and prophylactic indications
for ﬂuconazole, including those for cryptococcal disease, are
similar to those in adults. In low-birthweight infants, ﬂuconaz-
ole has been shown to reduce Candida infections [49,50]; on
the basis of these studies, ﬂuconazole prophylaxis is a valid
option for centres with a high frequency (>10%) of invasive
Candida infections in premature infants of <1000 g birthweight
or in the setting of a nosocomial outbreak with a ﬂuconazole-
susceptible Candida species. Population pharmacokinetics and
Monte Carlo simulation support a dose of 3 or 6 mg/kg twice
weekly during the ﬁrst 42 days of life for early prevention of
candidiasis in 23–29-week infants, and a 6 mg/kg dose every
72 h or 3 mg/kg daily for late prevention [39,48].
Itraconazole. The safety and pharmacokinetics of cyclodextrin
itraconazole oral solution in immunocompromised paediatric
patients ‡2 years of age have been studied in two phase II
clinical trials [51,52] in children with cancer, liver transplan-
tation or human immunodeﬁciency virus infection who
received the compound for treatment of oropharyngeal
candidiasis or as prophylaxis. On the basis of safety and efﬁ-
cacy, a dosage of 2.5 mg/kg twice daily was recommended
for the treatment of oropharyngeal candidiasis [52]. Popula-
tion-based pharmacokinetics in paediatric cystic ﬁbrosis and
allogeneic bone marrow transplant patients receiving the
oral solution or the capsule formulation as antifungal pro-
phylaxis, however, suggest a starting dose of 5 mg/kg twice
daily and TDM to maintain a target trough level of >0.5 lg/
mL [53]. Information on the intravenous hydroxypropyl-b-
cyclodextrin formulation is limited to a single-dose pharma-
cokinetic study in 33 children who received itraconazole at
2.5 mg/kg over 1 h. There was no safety issue, and analysis
of pharmacokinetic parameters suggests that the compound
can be administered with a weight-normalized dosing
approach [54].
Vomiting (12%), abnormal liver function tests (5%) and
abdominal pain (3%) were the most common adverse effects
considered to be related to cyclodextrin itraconazole solu-
tion in an open study in 103 neutropenic paediatric patients
who received the drug at 5 mg/kg daily for antifungal prophy-
laxis; 18% of patients withdrew from the study because of
adverse events [55]. Safety data on the intravenous cyclodex-
trin formulation in paediatric patients are limited to a single-
dose pharmacokinetic trial [54]; similarly, only anecdotal
reports have been published on the use of itraconazole in
the neonatal setting.
Therapeutic and prophylactic indications for itraconazole
in the settings of superﬁcial and invasive mycoses have been
reviewed elsewhere [25]. Itraconazole is not approved for
use in individuals <18 years of age, and can therefore only
be used off-label. On the basis of published pharmacokinetic
and safety data, the starting dosage range for the oral solu-
tion of itraconazole in paediatric patients beyond the neona-
tal period is 5 mg/kg daily in two divided doses. The
recommended target trough level is >0.5 lg/mL of the par-
ent itraconazole by HPLC [25]. Multiple-dose pharmacoki-
netic data for intravenous itraconazole are currently lacking;
the dosage regimen utilized in the published adult studies is
200 mg twice daily for 2 days, followed by 200 mg daily for a
maximum of 12 days [56].
New Agents and Current Status of
Paediatric Development
New antifungal triazoles
Voriconazole. Voriconazole is a synthetic oral and parenteral
antifungal triazole with activity against a wide spectrum of
clinically important yeasts and moulds (Fig. 2; Table 3). Voric-
onazole is currently approved for the treatment of invasive
aspergillosis, fusariosis and scedosporiosis, and for the pri-
mary treatment of invasive candidiasis in non-neutropenic
patients. For patients aged 12 years and above, the recom-
mended intravenous dosages are 6 mg/kg twice daily on
day 1, followed by 4 mg/kg twice daily; the oral dosages are
400 mg twice daily on day 1 (<40 kg, 200 mg twice daily),
followed by 200 mg twice daily (<40 kg, 100 mg twice daily).
Paediatric patients 2–11 years of age have a higher capac-
ity for elimination of voriconazole per kilogram of body-
weight than healthy adult volunteers, resulting in a lower,
TABLE 3. Principal pharmacokinetic properties of the new
antifungal triazoles posaconazole and voriconazole
Posaconazole Voriconazole
Formulation Oral/intravenous Oral/intravenous
Dose linearity Yes No
Oral bioavailability (%) >50 >90
Protein binding (%) >95 58
Volume of distribution (L/kg) >5 2
Elimination half-life (h) 25 6
Substrate/inhibitor of CYP450 3A4 3A4, 2C9, 2C19
Elimination via:
Faeces (%/% metabolites) 77/– <20/?
Urine (%/% metabolites) 14/14 80/78
Data compiled from [57,66].
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potentially non-therapeutic, exposure at similar dosages
[57]. In vitro studies with liver microsomes suggest that
this differential clearance is attributable to faster action
of CYP2C19 and ﬂavin-containing monooxygenase 3 in
N-oxidizing voriconazole in children [58]. In the interim, an
intra-individual dosage escalation study has been completed;
on the basis of the population-based analysis of the dataset
of this and the initial dose-ﬁnding study, an intravenous dos-
age of 7 mg/kg twice daily and an oral dosage of 200 mg
twice daily (oral suspension) without loading dosages has
been approved in the European Union for children
2–11 years of age [59]. A very recent population-based
analysis in 46 patients with a median age of 12 years (range,
0.8–20.5 years) found a pharmacodynamic association
between a voriconazole trough concentration of >1000 ng/
mL and survival; simulations predicted that an intravenous
dose of 7 mg/kg or an oral dose of 200 mg twice daily would
achieve a trough >1000 ng/mL in most patients, including
those ‡12 years of age [60]. Taken together, these data raise
questions, as in adults, about the optimal dose, the dosing
target and the need for TDM of voriconazole in paediatric
patients aged ‡2 years. It is of note that for children
<2 years of age, no systematic pharmacokinetic data exist, so
that dosing is empirical [61].
Data for larger cohorts of voriconazole-treated paediatric
patients are quite limited. Of 58 immunocompromised chil-
dren with invasive fungal infections, 26 (45%) had a complete
or partial response; in four patients (7%), the drug was discon-
tinued because of intolerance. A total of 23 patients had voric-
onazole-related adverse events, most commonly elevations of
hepatic transaminases or bilirubin (n = 8), skin rash (n = 8),
abnormal vision (n = 3) and photosensitivity reactions (n = 3)
[62]. In a retrospective cohort study in 37 immunocompro-
mised children and adolescents who received the drug for a
mean duration of 174 days, grade I or II adverse events were
observed in 19 patients (51%); the most frequent events
included transient increases in hepatic transaminases (19) and
transient visual disturbances (ﬁve). Four patients experienced
grade III/IV adverse events, and in three (8%) the drug was
permanently discontinued [63]. It is of note that, apart from
more serious hepatic adverse events, a possible link between
long-term use of voriconazole, immunosuppression and
chronic phototoxicity with aggressive squamous cell carci-
noma has been reported in adult and paediatric patients
[64]. Further clinical trials in paediatric patients initiated by
the manufacturer are currently underway to collect support-
ive data on dosing, safety and antifungal efﬁcacy.
Posaconazole. Posaconazole is a novel oral antifungal triazole
with potent and broad-spectrum activity against opportunistic,
endemic and dermatophytic fungi in vitro (Fig. 2; Table 3).
Importantly, posaconazole also possesses activity against
zygomycetes both in vitro and in vivo, distinguishing it from all
available azoles [65].
Posaconazole has been approved in the European Union
in patients ‡18 years of age for second-line treatment of
aspergillosis, fusariosis, chromoblastomycosis and coccidioi-
domycosis. In addition, posaconazole is approved for prophy-
laxis in high-risk patients with acute myeloid leukaemia/
myelodysplastic syndrome and in haematopoietic stem cell
transplant patients with graft-versus-host disease. The rec-
ommended daily dosage for salvage treatment is 400 mg
twice daily given with food; for patients not tolerating solid
food, a dosage of 200 mg four times daily is recommended,
preferably together with a nutritional supplement. The dos-
age for prophylaxis is 200 mg three times daily [65].
The pharmacokinetics of posaconazole in paediatric
patients <18 years of age have not yet been studied system-
atically. Limited data obtained in 12 paediatric subjects
‡8 years of age indicate no fundamental differences in trough
plasma concentrations as compared with adults [66]. Success-
ful salvage treatment with posaconazole has been reported in
5/11 and 6/10 paediatric subjects with invasive fungal infec-
tions, which appears to be similar to the outcome in the
adult population (15th ECCMID, Abstract P774; 67, Blune J,
2005). A paediatric development programme has been initi-
ated by the manufacturer to deﬁne dosages, safety and toler-
ance in paediatric patients beyond the neonatal period.
Echinocandin lipopeptides
The echinocandins are a distinct class of intravenous semi-
synthetic amphiphilic lipopeptides that act by inhibiting the
synthesis of 1,3-b-D-glucan in the fungal cell wall. Over the
past decade, three compounds with similar spectra, pharma-
cokinetics, safety and antifungal efﬁcacies have been devel-
oped: anidulafungin (Eraxis), caspofungin (Cancidas) and
micafungin (Mycamine) (Fig. 3; Table 4).
Anidulafungin. Anidulafungin is licensed in the European Union
for primary therapy in non-neutropenic adult patients
(‡18 years of age) with invasive Candida infections. The rec-
ommended dose regimen consists of 100 mg (day 1,
200 mg), administered at a rate not exceeding 1.1 mg/min.
A paediatric phase I/II multicentre study on the pharmaco-
kinetics and safety of anidulafungin has been completed in 19
granulocytopenic children with cancer. Patients were divided
into two age cohorts (2–11 and 12–17 years) and were
enrolled into sequential groups to receive 0.75 or 1.5 mg/kg
daily [68]. No drug-related serious adverse events were
recorded. Pharmacokinetic parameters were similar across
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age groups and dosage cohorts, and similar to those in adult
subjects. Following single and multiple daily doses of 0.75
and 1.5 mg/kg, plasma concentration data corresponded to
those in adults following a daily 50-mg and 100-mg dose,
respectively. The manufacturer’s paediatric development pro-
gramme is at an advanced stage.
Caspofungin. Caspofungin is licensed in the European Union
for adult and paediatric patients, including neonates, for
second-line therapy of invasive aspergillosis, for primary ther-
apy in non-neutropenic patients with invasive Candida infec-
tions, and for empirical antifungal therapy in persistently
febrile granulocytopenic patients. The recommended dose
regimen in adults consists of a single 70-mg loading dose on
day 1, followed by 50 mg daily thereafter, administered over
1 h [69].
In children and adolescents 2–17 years of age, the pharma-
cokinetics and safety of caspofungin were investigated with
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FIG. 3. Chemical structures of anidulafungin, caspofungin and micafungin. The echinocandins are amphoteric cyclic lipopeptides with a hexapep-
tide core that is linked to a variably conﬁgured lipid side chain.
TABLE 4. Principal pharmacokinetic
properties of the echinocandin
lipopeptides caspofungin, anidula-
fungin and micafungin
Caspofungin Anidulafungin Micafungin
Formulation Intravenous Intravenous Intravenous
Dose linearity Yes Yes Yes
Oral bioavailability (%) NA NA NA
Protein binding (%) 97 84 99
Volume of distribution (L/kg) NA 0.7–0.9 0.24
Elimination half-life (h) 8–10 24 15
Substrate/inhibitor of CYP450 NA NA NA
Routes of elimination Degradation/metabolism,
urine > faeces
Degradation only,
faeces
Metabolism,
faeces > urine
Data compiled from [67,71,78].
NA, not applicable.
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either a weight-based or a body surface area regimen.
Whereas 1 mg/kg daily achieved suboptimal exposure, dosing
with 50 mg/m2 daily provided similar or slightly higher as in
adults [70]. In conjunction with similar pharmacokinetic data
obtained in small children [71], the dosage of 50 mg/m2 daily
(day 1, 70 mg/m2 daily; maximum daily dose, 70 mg) was
selected for paediatric patients between 3 months and
17 years of age. This dosing regimen has been conﬁrmed by
a population-based pharmacokinetic study including 124 pae-
diatric patients 3 months to 17 years enrolled in four clinical
trials (48th ICAAC, Abstract A-006, Lee J, 2008). In
neonates up to a postnatal age of 3 months, limited pharma-
cokinetic data obtained in a small cohort of patients suggest
that a dosage of 25 mg/m2 daily results in similar exposures
as 50 mg/m2 daily in older patients [72].
Caspofungin is well tolerated in paediatric patients. In the
above-mentioned phase I/II dose-ﬁnding trials, none of the
patients developed a serious drug-related adverse event or
had the drug discontinued because of toxicity [70–72]. In a
phase III comparative estimation trial with safety as the pri-
mary objective, 82 patients between the ages of 2 and
17 years with persistent fever and neutropenia were ran-
domly assigned to receive caspofungin or liposomal ampho-
tericin B (3 mg/kg daily) in a 2 : 1 ratio. Rates of drug-
related adverse events were similar (clinical, 48.2% vs. 46.2%;
laboratory, 10.7% vs. 19.2%); serious drug-related adverse
events occurred in 1.8% of caspofungin-treated and in 11.5%
of amphotericin B-treated patients. Overall success rates
were not different [18]. In the combined analysis of caspo-
fungin safety in all ﬁve clinical registration trials involving 171
paediatric patients aged 1 week to 17 years, the most com-
mon drug-related adverse events were fever (11.7%),
increased alanine transaminase (6.5%), and rash (4.7%); few
events were serious (0.6%) or required treatment discontin-
uation (1.2%) [73]. A favourable safety proﬁle has also been
reported in immunocompromised paediatric patients who
received the compound for various indications outside of
clinical registration trials, mostly in combination with other
antifungal agents [74,75], and in neonates with refractory
invasive candidiasis [76,77].
Micafungin. Micafungin is licensed in the European Union for
neonates, children and adults for the treatment of invasive
candidiasis and as prophylaxis for Candida infections in
patients with allogeneic haematopoietic stem cell transplan-
tation and those with prolonged neutropenia; it is also
licensed for the treatment of oesophageal candidiasis in
individuals 16 years and older. The recommended dosage is
100 mg daily for invasive candidiasis (£40 kg bodyweight,
2 mg/kg) with the option of dose escalation to 200 mg daily
or 4 mg/kg daily, 150 mg daily for oesophageal candidiasis
(£40 kg, 3 mg/kg), and 50 mg daily (£40 kg, 1 mg/kg) for
prevention.
The pharmacokinetics of micafungin have been studied in
70 children and adolescents in an open-label, sequential
group, dose escalation study of empirical therapy in febrile
granulocytopenic children aged 2–17 years. At dosages rang-
ing from 0.5 to 3.0 mg/kg daily, the pharmacokinetics were
linear and the pharmacokinetic parameters were similar to
those observed in adults [78]. Population-based pharmacoki-
netic modelling of the data revealed that clearance in smaller
children was higher than predicted on the basis of weight
alone, requiring a relative dosage increase to ensure expo-
sure comparable to that in older children; however, dosages
of 2 and 4 mg/kg in the children achieved at least similar
exposures as 100 and 200 mg, respectively, in adults [79].
The pharmacokinetics in neonates were explored in a pha-
se I, single-dose, multicentre, open-label, sequential dose trial
of micafungin (0.75, 1.5 and 3.0 mg/kg) in 18 premature
infants weighing >1000 g. On average, the half-life was
shorter and the clearance was more rapid than in older chil-
dren and adults [80]. Population pharmacokinetic modelling
of the neonatal pharmacokinetic data and Monte Carlo simu-
lation suggest that a larger neonatal dose is required to pro-
duce drug exposure comparable to those predicted on the
basis of weight in children and adults; additional population
pharmacokinetics based on open-label pharmacokinetic stud-
ies with doses up to 15 mg/kg daily support a target dose of
10 mg/kg for neonates, particularly in view of the substantial
risk of secondary brain involvement [81–84]. Although the
treatment results in the pivotal candidaemia study showed
no sign of decreased efﬁcacy at dosages between 2 and
4 mg/kg in this population [17], we recommend a dose of
at least 4 mg/kg in neonates with invasive candidiasis and a
dose of 10 mg/kg in the case of central nervous system
involvement.
The comparative safety of micafungin was investigated in
the paediatric subpopulation of a double-blind, phase III trial
in patients with invasive candidiasis or candidaemia. Patients
were randomized to receive intravenous micafungin (2 mg/kg
daily) or liposomal amphotericin B (3 mg/kg daily) for a mini-
mum of 14 days. There was no difference in the success
rates (69.2% vs. 74.1%). The incidence of serious adverse
events (3.8% vs. 9.3%) and the rate of patients discontinuing
therapy because of an adverse event (3.8% vs. 16.7%) were
lower in micafungin-treated patients [17]. In a pooled analysis
of adverse event data from six clinical trials including 296
patients (median daily dose, 1.7 mg/kg (range: 0.4–8.6 mg/kg);
median treatment duration, 15 days (range: 1–425 days),
26.7% of patients had a treatment-related adverse event and
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TABLE 5. Summary of current concepts for management of invasive fungal infections in paediatric patientsa
Condition Treatment recommendation Comments
Candidaemia and deeply
invasive candidiasis
First-line options approved by the FDA and/or the
EMA:
Liposomal amphotericin B (3 mg/kg daily)
Fluconazole (8–12 mg/kg daily)
Caspofungin (50 mg/m2 daily; day 1,
70 mg/m2)
Micafungin (<40 kg, 2–4 mg/kg; ‡40 kg,
100–200 mg daily)
Patients who have received azole prophylaxis, are
haemodynamically unstable or granulocytopenic, are
colonized with Candida glabrata or Candida krusei or
are admitted to institutions with a high frequency of
these organisms should receive a polyene or
echinocandin up front
Second-line options:
Amphotericin B lipid complex (5 mg/kg daily)
Voriconazole (4 mg/kg twice daily in children
‡12 years)
Central venous catheters should be removed
promptly if feasible
Neutropenic patients should receive
colony-stimulating factors, and in immunosuppressed
patients, steroids should be reduced, discontinued
or replaced
Treatment of other forms of invasive candidiasis
(endocarditis, peritonitis and meningitis) is ill-deﬁned
and based on pharmacological considerations such
as a cidal mode of action and water solubility, and
always includes the evaluation of surgical
interventions. The additional use of ﬂucytosine has a
role in these situations
The recommended duration of therapy for
uncomplicated candidaemia is 14 days after
clearance from the bloodstream and resolution of
all symptoms
Following clearance from the bloodstream and
clinical stabilization, oral consolidation with
ﬂuconazole is feasible for susceptible isolates
Fundoscopy is mandatory prior to end of treatment,
to rule out endophthalmitis
Invasive aspergillosis First-line options approved by the FDA and/or the
EMA:
Voriconazole (4 mg/kg twice daily in children
‡12 years; 7 mg/kg twice daily ‡2 to 11 years)
Liposomal amphotericin B (3 mg/kg daily)
Adjunctive surgical interventions need consideration
in skin and soft tissue infections, sinus infections,
impeding erosion of pulmonary arteries, and
operable CNS and lung lesions
Second-line options:
Amphotericin B lipid complex (5 mg/kg daily)
Caspofungin (50 mg/m2 daily; day 1,
70 mg/m2)
G-CSF or GM-CSF is indicated in neutropenic
patients, and reduction, discontinuation or
replacement of steroids in immunosuppressed
patients
Voriconazole is currently recommended for
Aspergillus terreus infections and infections affecting
the CNS
The duration of therapy is individual and determined
by the clinical and microbiological response
In settings with a high frequency of zygomycosis,
voriconazole may not be a choice for pre-emptive
therapy
Clinical stabilization and at least a partial response
provided; treatment can be consolidated with oral
therapies
Dose escalation of liposomal amphotericin B to
10 mg/kg daily for the initial 14 days of treatment
was not beneﬁcial in a randomized comparative trial
Combination of standard doses of either
voriconazole or liposomal amphotericin B with
caspofungin is promising, but valid clinical data are
currently lacking
Emerging fungal pathogens Amphotericin B is used as primary therapy for
zygomycosis; posaconazole has shown encouraging
clinical activity in the second-line setting
Treatment of infections by the emerging fungal
pathogens is an interdisciplinary challenge and needs
to be individualized on the basis of the isolate, the
site of the infection, and the patient’s response to
treatment
Limited and uncontrolled data indicate an important
role of both voriconazole and posaconazole for
treatment of Scedosporium and Fusarium infections
Empirical antifungal therapy Options approved by the FDA and/or the EMA in
this indication:
Liposomal amphotericin B (1–3 mg/kg daily)
Caspofungin (50 mg/m2 daily; day 1,
70 mg/m2)
Empirical antifungal therapy is an established standard
of care in haemato-oncological patients with
prolonged neutropenia (ANC <500 for ‡10 days)
and refractory or new fever that provides targeted
prevention in a high-risk setting
Antifungal prophylaxis Prophylactic ﬂuconazole (8–12 mg/kg daily) remains a
standard post-allogeneic haematopoietic stem cell
transplantation; alternatives may include the use of
voriconazole or micafungin (1 mg/kg daily)
–
In patients with GVHD and increased
immunosuppression, posaconazole (200 mg three
times daily) has been shown to prevent IFIs and
invasive aspergillosis
Posaconazole may be given to children >12 years
with high-risk haematological malignancies, or used
for augmented immunosuppression for GVHD and
voriconazole in younger children. Alternatives
include liposomal amphotericin B (1 mg/kg
every other day) or micafungin (1 mg/kg daily)
In adults with AML/MDS, posaconazole (200 mg
three times daily) had a signiﬁcant impact on the
frequency of IFIs and, in particular, invasive
aspergillosis, coupled with an overall survival beneﬁt
Prophylaxis in very low
birthweight preterm
neonates
Four randomized controlled trials, including a
multicentre study, consistently reported signiﬁcant
decreases in colonization and infection by Candida
spp. in the treated infants. On pooling of the
results, ﬂuconazole reduced IFI risk by 75%, and
all-cause mortality by 24%
Fluconazole may be given as antifungal prophylaxis in
institutions with a substantial incidence (>5% to
10%) of invasive candidiasis in very low birthweight
infants or in outbreak situations
AML, acute myeloid leukaemia; ANC, absolute neutrophile count; CNS, central nervous system; EMA, European Medicines Agency; FDA, Food and Drug Administration;
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte–macrophage colony-stimulating factor; GVHD, graft-versus-host disease; IFI, invasive fungal infection;
MDS, myelodysplastic syndrome.
aModiﬁed from Dornbusch et al. [85]. For details on the selected treatment options, please consult the text.
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2.4% had a treatment-related adverse events that led to
treatment discontinuation. No trends were seen with
respect to dose or duration of treatment, and the types and
rates of events were similar to those observed in adults
(47th ICAAC, Abstract M-1162, Avvieta A, 2007).
In Europe, the Summary of Product Characteristics for
micafungin recommends careful monitoring of liver function,
and early discontinuation in the presence of signiﬁcant and
persistent elevation of alanine transaminase/aspartate trans-
aminase values. It also recommends that micafungin treat-
ment should be conducted with a careful risk–beneﬁt
assessment, particularly in patients with liver diseases or
receiving concomitant hepatotoxic/genotoxic therapies (Myc-
amine SPC; http://www.ema.europa.eu/ena/index.jsp.curl
=pages/medicines/human/medicines/000734/human_med_0009
(last accessed 14 May 2010)). This recommendation is based
on exposure-dependent development of foci of altered he-
patocytes (signiﬁcant) and liver tumours (non-signiﬁcant) in a
long-term exposure model in rats. The human relevance of
this ﬁnding is presently not known. Similar, comparable pre-
clinical studies for anidulafungin and caspofungin are not in
the public domain.
Conclusions
Paediatric age groups display important differences in host
biology, predisposing conditions, epidemiology and presenta-
tion of fungal infections relative to the adult population. Dur-
ing the past decade, several new antifungal agents have been
developed. Although not all of these agents are yet approved
for children, the development of antifungal agents for paedi-
atric use has moved forwards in an exemplary manner. Inva-
sive fungal infections will remain important causes of
morbidity and mortality in immunocompromised paediatric
patients. Whereas the availability of new therapeutic options
is an important advance, antifungal therapy has become
increasingly complex (Table 5), and a thorough understanding
of the available antifungal armamentarium is essential for the
successful management of the individual patient.
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